Literature DB >> 2890117

Emesis induced by cisplatin in the ferret as a model for the detection of anti-emetic drugs.

B Costall1, A M Domeney, R J Naylor, F D Tattersall.   

Abstract

The intravenous injection of cisplatin in the ferret caused a consistent emetic (vomiting/retching) response. Emesis induced by cisplatin was abolished by the 5-hydroxytryptamine (5-HT) M-receptor antagonists ICS205-930, zacopride, dazopride and metoclopramide. The neuroleptic agents haloperidol, fluphenazine, domperidone, sulpiride and tiapride also antagonized emesis induced by cisplatin but only a proportion of the animals were completely protected and diazepam and prednisolone only reduced the intensity of the response. It is concluded that compounds used in the clinic to antagonise emesis induced by chemotherapy are effective in the ferret model. Antagonism of emesis induced by cisplatin in the ferret was most potently achieved by the use of the 5-HT M-receptor antagonists ICS205-930 and zacopride. However, an antagonism of dopamine receptors would appear relevant to the anti-emetic effects of the neuroleptic agents and may contribute to the anti-emetic effects of metoclopramide. Diazepam and prednisolone exert their modest antagonism by unknown mechanisms. The use of the 5-HT M-receptor antagonists is revealed as a novel approach to the treatment of emesis induced by cisplatin.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2890117     DOI: 10.1016/0028-3908(87)90094-3

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  12 in total

1.  Topographical distribution of 5-HT3 receptor recognition sites in the ferret brain stem.

Authors:  J M Barnes; N M Barnes; B Costall; I L Naylor; R J Naylor; J A Rudd
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-07       Impact factor: 3.000

2.  Mechanism of gastrointestinal abnormal motor activity induced by cisplatin in conscious dogs.

Authors:  Hiroyuki Ando; Erito Mochiki; Tetsuro Ohno; Mitsuhiro Yanai; Yoshitaka Toyomasu; Kyoichi Ogata; Yuichi Tabe; Ryuusuke Aihara; Toshihiro Nakabayashi; Takayuki Asao; Hiroyuki Kuwano
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

3.  A serotonergic mechanism for the metoclopramide-induced increase in aldosterone level?

Authors:  C A Rizzi
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

4.  Cisplatin-induced early and delayed emesis in the pigeon.

Authors:  S Tanihata; H Igarashi; M Suzuki; T Uchiyama
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

Review 5.  Physiology of chemotherapy-induced emesis and antiemetic therapy. Predictive models for evaluation of new compounds.

Authors:  C Veyrat-Follet; R Farinotti; J L Palmer
Journal:  Drugs       Date:  1997-02       Impact factor: 9.546

Review 6.  Tropisetron. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic.

Authors:  C R Lee; G L Plosker; D McTavish
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

7.  Dose-ranging evaluation of the substituted benzamide dazopride when used as an antiemetic in patients receiving anticancer chemotherapy.

Authors:  S C Grant; M G Kris; R J Gralla; R A Clark; L B Tyson
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  Tropisetron (Navoban) in the prevention of chemotherapy-induced nausea and vomiting--the Nordic experience.

Authors:  B Sorbe; H Andersson; M Schmidt; M Söderberg; T Högberg; L Wernstedt; E T Janson; B Ehrnström; M Kjaer; H Havsteen
Journal:  Support Care Cancer       Date:  1994-11       Impact factor: 3.603

9.  Receptor mechanism and antiemetic activity of structurally-diverse cannabinoids against radiation-induced emesis in the least shrew.

Authors:  Nissar A Darmani; Jano J Janoyan; Jennifer Crim; Juan Ramirez
Journal:  Eur J Pharmacol       Date:  2007-02-16       Impact factor: 4.432

10.  5-HT3 receptor antagonism by anpirtoline, a mixed 5-HT1 receptor agonist/5-HT3 receptor antagonist.

Authors:  M Göthert; M Hamon; M Barann; H Bönisch; H Gozlan; R Laguzzi; P Metzenauer; B Nickel; I Szelenyi
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.